A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
about
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyMedical management of Crohn's disease.Distinct Methylation of IFNG in the GutDistinct profiles of effector cytokines mark the different phases of Crohn's diseaseLRRK2 is involved in the IFN-gamma response and host response to pathogens.A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice.Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis.Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling.Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient miceInterfering with interferons in inflammatory bowel disease.Cytokine Networks and T-Cell Subsets in Inflammatory Bowel DiseasesInvestigational new drugs in the treatment of inflammatory bowel disease: a review.Biologics in Crohn's disease: searching indicators for outcome.Pharmacogenetics of Crohn's disease.Overview of biologic therapy for Crohn's disease.Cytokine-receptor interactions as drug targets.Investigational agents for Crohn's disease.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease.Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases.Cells, cytokines and inflammatory bowel disease: a clinical perspective.Cytokine blockade in inflammatory bowel diseases.Biological therapies for inflammatory bowel disease: controversies and future options.What's the next best cytokine target in IBD?Investigational cytokine-targeted therapies for ulcerative colitis.Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.The balance of intestinal Foxp3+ regulatory T cells and Th17 cells and its biological significance.Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.Advances in understanding the immunopathology of sarcoidosis and implications on therapy.Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model.Emerging drugs to treat Crohn's disease.Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis.Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation.T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype.Immunological pathogenesis of inflammatory bowel disease.
P2860
Q28253174-EF3307A4-13B5-4A7E-9FAD-298DA920D89DQ34046139-F0BE3034-306A-449A-A984-982606784FE3Q34207648-F1FEA8F4-E957-4943-91DE-A8AFADEA1A2EQ34563301-1AFD6EA8-DF30-4FF2-9691-40CBF8CD5E00Q35164433-C58E75DF-2333-4B51-97C1-E324AE226E5DQ35207745-16E5D1F2-A152-4B6F-B750-4235B483FC45Q35688870-2BAEE454-E31B-41AD-BFB0-09BD8F44CD8DQ35699353-9A4C7883-067B-44B1-94F9-7D457B13FE09Q35875927-8FAD1322-13EA-47F0-AE9F-CFACC25EBD4BQ36042041-DCD4C560-9EA5-43C3-A063-F7844D0F470DQ36540026-614F0757-58FF-46A3-82DD-E69C0848AE06Q36818290-F3D1B254-CFCE-44FE-9EB1-9993F95F7EDAQ36890446-07EF45F1-7AD4-4495-BC5E-3896773CB2DDQ36909385-23401413-2D02-4EEC-8F49-0C246FE61634Q37205946-0E8072D7-6D7B-448D-9E3E-769C2DAAF428Q37547257-4A96BD86-0B16-4BBF-9A69-516445578229Q37771522-7C462F57-B616-4E37-BBC1-64636D865071Q37788217-C117455B-117B-47E1-B1E3-0793CEEA334CQ37847059-85F61B4C-299D-415A-9CB5-5EB33B301457Q37849582-349036C1-D88A-43D5-BCCA-77B25857BA84Q37909490-73CAFCB7-FD49-4E68-A19B-D078B77ADFA7Q37948155-61C4E86C-B7F8-4321-ACDB-4DC5A5AEC47DQ37952792-24503ECA-36D1-4FD4-BEF2-6E44AACA52A6Q37960183-5A1DB522-9CB3-4BA1-BE70-84A82B78897FQ38003092-60692DA1-3FAA-4230-B14D-C2269A6B4CD8Q38117175-2E6E58B4-7F4C-45B3-BD09-B9A76A8116CDQ38138195-70E224AF-5687-44E5-A1AC-399F27A7E11CQ38177338-4E7910D8-A1BA-4D42-9B16-BD854AA525E8Q38183860-590D2729-AA33-4930-A2FA-775260A78089Q38253844-1DEAFFEA-26CD-4AAB-BDB0-A26773E391E5Q38665573-0D590E9E-83C0-41C3-A7AB-EE9277E06C85Q38805575-D6FA4D47-B390-46CC-A212-9EA36E97AD59Q38814035-9F001848-75A0-4EA7-924C-D625B72ED95BQ39121473-E5824D77-D244-43FE-AA75-20D62B47DA36Q39625243-EA3776C5-66BB-4642-B657-6123806E3115Q39881787-89511F51-D479-4777-943C-7A516832F4A9Q39985099-29F3386A-C09E-4A51-8753-C5DAF68BB8EFQ47221352-C0FE19C0-FA74-4DA2-BD99-9E7C3E99B8A6Q49579233-AD46ED12-BFBE-4428-833B-6A26F9EBD82BQ50042967-3F076E73-538B-4E0E-91B9-274C0646A2D1
P2860
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A dose escalating, placebo con ...... rate to severe Crohn's disease
@ast
A dose escalating, placebo con ...... rate to severe Crohn's disease
@en
A dose escalating, placebo con ...... rate to severe Crohn's disease
@nl
type
label
A dose escalating, placebo con ...... rate to severe Crohn's disease
@ast
A dose escalating, placebo con ...... rate to severe Crohn's disease
@en
A dose escalating, placebo con ...... rate to severe Crohn's disease
@nl
prefLabel
A dose escalating, placebo con ...... rate to severe Crohn's disease
@ast
A dose escalating, placebo con ...... rate to severe Crohn's disease
@en
A dose escalating, placebo con ...... rate to severe Crohn's disease
@nl
P2093
P2860
P921
P356
P1433
P1476
A dose escalating, placebo con ...... rate to severe Crohn's disease
@en
P2093
B Oldenburg
D W Hommes
G Van Assche
J-F Colombel
J-P Gendre
P2860
P304
P356
10.1136/GUT.2005.079434
P407
P577
2006-08-01T00:00:00Z